Visão geral da empresa
ProQR Therapeutics N.V. operates as a clinical-stage biotechnology company dedicated to the discovery and development of novel therapeutic medicines for genetic disorders with unmet medical needs. The firm leverages its proprietary Axiomer RNA editing technology to create treatments that address complex genetic conditions, positioning itself within the broader healthcare sector where innovation drives long-term value creation. With a market capitalization of $192.81 million, an annual revenue of $16.35 million, and an employee base of 186, the company maintains a relatively small operational footprint typical of early-stage biotech firms. These financial figures indicate that ProQR is a micro-cap entity focused on high-risk, high-reward research and development rather than established commercial profitability, reflecting a strategic priority on advancing its lead product candidate, AX-081, through clinical trials to achieve future commercialization milestones.
Saúde financeira
The company reported a total revenue of $16.35 million over the trailing twelve months, yet it recorded a net income of $-42,184,000, revealing a significant cost structure where operating expenses substantially exceed current sales generation. This disparity between revenue and net income highlights the heavy investment required in research, development, and clinical activities inherent to the biotechnology industry before products reach the market. Free cash flow stands at $-32,042,376, indicating that the company is consuming cash reserves to fund its operations and development pipeline rather than generating surplus liquidity. Despite these outflows, the balance sheet retains $92.41 million in cash against $15.96 million in debt, suggesting a net cash position that provides substantial financial flexibility for ongoing R&D efforts. Gross margin is reported at 100.0%, a characteristic metric for early-stage biotech companies with no cost of goods sold prior to commercialization, while the operating margin of -192.9% and profit margin of -258.1% underscore the aggressive burn rate required to advance clinical programs. The debt-to-equity ratio of 32.33 further illustrates a capital structure heavily reliant on equity financing rather than leverage, and the current ratio of 3.09 demonstrates strong short-term liquidity, ensuring the company can meet its obligations without immediate refinancing risk. Finally, the return on equity of -61.2% and return on assets of -19.3% reflect the reality that management effectiveness at this stage is measured by asset accumulation and progress in clinical milestones rather than immediate profitability.
Avaliação de valorização
The trailing P/E ratio is listed as N/A due to negative earnings, while the forward P/E is -3.89, a negative figure that implies the market anticipates continued losses in the near term rather than immediate profitability. The price-to-book ratio of 3.38 suggests that the market values the company at a significant premium relative to its book value, likely driven by the intangible value of its Axiomer RNA editing platform and intellectual property portfolio. Alternative valuation metrics such as the price-to-sales ratio of 11.79 and an EV/EBITDA of -2.73 indicate that investors are pricing the stock based on future revenue potential and pipeline value rather than current earnings power. The 52-week trading range spans from a low of $1.07 to a high of $3.10, providing a clear historical context for price volatility and investor sentiment over the past year. The beta value of 0.09 is exceptionally low, indicating that the stock price exhibits minimal volatility relative to the broader market, likely due to its small market cap and lack of correlation with general market indices.
Growth & Income
Revenue growth year-over-year stands at 6.1%, while earnings growth is marked as N/A due to the company's continued net losses, indicating that top-line expansion is occurring without a corresponding improvement in bottom-line profitability. The company does not distribute dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available earnings are retained within the organization to fund research and development activities. This reinvestment strategy is standard for clinical-stage biotechs, where capital is directed toward advancing the lead product candidate, AX-081, and expanding the clinical pipeline rather than returning capital to shareholders. The overall growth and income profile characterizes ProQR as a capital-intensive growth company that prioritizes technological advancement and clinical trial completion over current income generation or shareholder payouts.